Marie‐Christine Chartier‐Harlin

This study identifies a regulatory feedback loop between LRRK2 and PP2A phosphatases in Parkinson's disease, showing that LRRK2 phosphorylates PP2A to disrupt its function and contribute to neuronal death.

This study conducts a genome-wide association study of copy number variations in Parkinson's disease, identifying a significant PRKN deletion but limited replication in an independent dataset.

The paper identifies urinary protein signatures linked to LRRK2 dysfunction in Parkinson's disease using multi-cohort proteomics and machine learning, showing cross-species relevance and potential as pharmacodynamic markers.

Peripheral blood-derived cells can be employed to stratify Parkinson's disease patients most likely to respond to LRRK2-related therapeutics.

This paper performs a large meta-analysis of GWAS in dementia with Lewy bodies, identifying sex-specific genetic risk signals and highlighting the need for larger cohorts.

The paper identifies two novel LRRK2 variants associated with familial Parkinson's disease and shows they alter phosphorylation and kinase activity.

The paper identifies transcriptomic signatures of brain regional vulnerability to Parkinson’s disease by analyzing gene expression patterns across Braak Lewy body stages in human brain datasets.